Search clinical trials for: GSK573719 125mcg

Total 754 results

GlaxoSmithKline

Completed

28-day Repeat Dose Study of GSK573719

Pulmonary Disease, Chronic Obstructive

United States, Estonia, Germany, Poland
GlaxoSmithKline

Completed

A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (DB2113361)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Japan, Ukraine, Estonia, Belgium, France, Sweden, Netherlands, Philippines, Denmark, Hungary, Norway, Slovakia
GlaxoSmithKline

Completed

Dose-Ranging Study Of GSK233705B In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Germany, Romania, Bulgaria, Argentina, Canada, Chile, Philippines, South Africa, Thailand, Netherlands, Korea, Republic of, Hungary, United Kingdom
GlaxoSmithKline

Completed

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (COPD nDPI)

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Chile, South Africa, Romania, Slovakia
GlaxoSmithKline

Completed

Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

A Study of GSK573719 in Healthy Japanese Male Subjects

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

QTc Study GSK573719+GW642444

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment

Pulmonary Disease, Chronic Obstructive

Czechia, Hungary
GlaxoSmithKline

Completed

A Study to Assess the Effects of GSK573719/VI Combination and GSK573719 Monotherapy in Subjects With Moderate Hepatic Impairment and Matched Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

Hungary, Slovakia
GlaxoSmithKline

Completed

A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD (DB2113373)

Pulmonary Disease, Chronic Obstructive

Japan, Russian Federation, Spain, United States, Bulgaria, Canada, Poland, South Africa, Thailand, Mexico, Chile, Greece, Czechia
GlaxoSmithKline

Completed

A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

Taiwan, Thailand, China, Philippines, Korea, Republic of
Faes Farma, S.A.

Completed

Efficacy and Safety of Calcifediol vs Placebo in Subjects With Vitamin D Deficiency (WORFEROL)

Vitamin D Deficiency | Vitamin D Insufficiency

Spain, France, Bulgaria, Czechia, Italy, Serbia, Slovakia
GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B (COPD)

Pulmonary Disease, Chronic Obstructive

South Africa, United States, Canada, Ukraine, United Kingdom, Denmark, Czechia
GlaxoSmithKline

Completed

A Study to Assess the Safety and Tolerability of Once Daily Inhaled Doses of GSK573719 Made With Magnesium Stearate in Subjects With Chronic Obstructive Pulmonary Disease(COPD)for 7 Days

Pulmonary Disease, Chronic Obstructive

United Kingdom
Shaheer A. Khan
AstraZeneca; Melanoma Research Alliance

Completed

Intermittent Selumetinib for Uveal Melanoma

Uveal Melanoma

United States
GlaxoSmithKline

Completed

Long-term Safety Study for GSK573719 in Japanese (AC4115361)

Pulmonary Disease, Chronic Obstructive

Japan
Baylor Research Institute

Not yet recruiting

Outcomes of Once-Daily ICS/LABA/LAMA Plus PRN Respiratory Therapy Treatments in Hospitalized Patients With COPD Exacerbations (Sundial-COPD)

Copd

United States
GlaxoSmithKline

Completed

A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Estonia, Canada, Chile, Germany, Peru, Philippines, Mexico, Korea, Republic of, Denmark, Russian Federation, Poland, Slovakia
GlaxoSmithKline

Completed

Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler.

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

GSK573719 IV Enabling Study

Pulmonary Disease, Chronic Obstructive

United Kingdom
Chengdu Zenitar Biomedical Technology Co., Ltd

Recruiting

Safety of Flunotinib Maleate Tablets for the Treatment of Patients With Myeloproliferative

Myeloproliferative Neoplasm (MPN) | Myelofibrosis，MF

China
GlaxoSmithKline

Completed

Long-term Safety Study for GSK573719/GW642444 in Japanese (DB2115362)

Pulmonary Disease, Chronic Obstructive

Japan
Chengdu Zenitar Biomedical Technology Co., Ltd

Not yet recruiting

Study of Flonoltinib Maleate Tablets in the Treatment of Proliferative Bone Marrow Tumors

Myeloproliferative Neoplasm (MPN) | Myelofibrosis，MF
GlaxoSmithKline

Completed

A Single Centre Randomized Study Evaluating The Safety And Tolerability Of GSK573719 In Healthy Volunteers

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function

Asthma

New Zealand
GlaxoSmithKline

Completed

Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

Germany, Japan, United States
Queen's University
GlaxoSmithKline

Completed

Effect of a New Combination Bronchodilator on Exercise in GOLD Stage II Moderate COPD

COPD

Canada
GlaxoSmithKline

Completed

A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719

Pulmonary Disease, Chronic Obstructive

Netherlands
GlaxoSmithKline

Completed

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Argentina, Australia, United States, Germany, Chile, Korea, Republic of, Mexico, Canada, South Africa, Romania
GlaxoSmithKline

Withdrawn

Aura Adolescent PK Study GSK2829332

Asthma
GlaxoSmithKline

Completed

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of GSK573719 (LAMA) and GW642444 (LABA)Administered Individually and Concurrently in Healthy Japanese Subjects (DB2113208)

Pulmonary Disease, Chronic Obstructive

Australia
Shire

Completed

Safety and Efficacy Study of SHP465 in Adults Aged 18-55 Years With Attention-deficit/ Hyperactivity Disorder (ADHD)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Shire

Completed

Study to Assess the Blood Concentrations and Actions of Recombinant Human Parathyroid Hormone (rhPTH [1-84]) When Given Once and Twice Daily to Participants With Hypoparathyroidism (PARALLAX)

Hypoparathyroidism

United States, Hungary, Canada, Denmark
GlaxoSmithKline

Completed

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Ukraine, Germany, Peru, Poland, France, Romania, Italy, Mexico
Shire

Completed

Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Theravance Biopharma
GlaxoSmithKline

Completed

Study of GSK961081 in Healthy Volunteer Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Evaluate the Safety, Efficacy and Dose Response of GSK573719 in Combination With Fluticasone Furoate in Subjects With Asthma (ILA115938)

Asthma

Argentina, Russian Federation, United States, Chile, Thailand
The University of Queensland
Syneos Health; Coalition for Epidemic Preparedness Innovations

Active, not recruiting

A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults

Covid19 | SARS-CoV2

Australia
Galera Therapeutics, Inc.

Completed

A Study Designed to Evaluate the Safety and Pharmacokinetics of Intravenously Administered Superoxide Dismutase Mimetic GC4711 in Healthy Volunteers

Healthy

Australia
GlaxoSmithKline

Completed

Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Idiopathic

Japan
Odense University Hospital

Completed

Antithyroid Drugs During Radioiodine Therapy

Graves Disease | Toxic Nodular Goitre

Denmark
University of Chicago

Completed

Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma

Pancreatic Adenocarcinoma

United States
Guangdong Zhongsheng Pharmaceutical Co., Ltd.

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults

Solid Tumor | Idiopathic Pulmonary Fibrosis(IPF)

China
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
The First Affiliated Hospital with Nanjing Medical University; Cancer Institute... and other collaborators

Unknown

Saftey and Efficacy of Pegfilgrastim in Preventing Chrmotherapy-induced Neutropenia (PEG-rhG-CSF)

Neutropenia

China
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

Pulmonary Disease, Chronic Obstructive

United States, Germany, Canada, Korea, Republic of
GlaxoSmithKline

Completed

Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.

Pulmonary Disease, Chronic Obstructive

United States, Korea, Republic of, Chile, Poland, Czech Republic
Daewoong Bio Inc.

Completed

Pharmacokinetics, Safety, and Tolerability of rhEGF Eye Drops in Healthy Male Subjects

Dry Eye Syndromes

Korea, Republic of
Napo Pharmaceuticals, Inc.

Completed

Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea

Acquired Immunodeficiency Syndrome | HIV/AIDS | Healthy Volunteers | Human Immunodeficiency Virus | HIV Diarrhea

United States
HK inno.N Corporation

Enrolling by invitation

PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects

Healthy

Korea, Republic of
The Affiliated Hospital of Qingdao University

Completed

A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers

Healthy Volunteers

China

Search clinical trials for: GSK573719 125mcg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahamas

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations